Resilient Collective

🦠 𝐂𝐨𝐮𝐥𝐝 𝐍𝐀𝐃𝐏𝐇 𝐎𝐱𝐢𝐝𝐚𝐬𝐞 𝐁𝐞 𝐭𝐡𝐞 𝐊𝐞𝐲 𝐭𝐨 𝐔𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠 𝐋𝐮𝐩𝐮𝐬? 🔬 Delve into the surprising dual functions of NADPH oxidase in lupus and its potential therapeutic implications. 🧬 𝐍𝐀𝐃𝐏𝐇 𝐨𝐱𝐢𝐝𝐚𝐬𝐞 (𝐍𝐎𝐗𝟐) 𝐡𝐚𝐬 𝐞𝐦𝐞𝐫𝐠𝐞𝐝 𝐚𝐬 𝐚 𝐜𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐩𝐥𝐚𝐲𝐞𝐫 𝐢𝐧 𝐬𝐲𝐬𝐭𝐞𝐦𝐢𝐜 𝐥𝐮𝐩𝐮𝐬 𝐞𝐫𝐲𝐭𝐡𝐞𝐦𝐚𝐭𝐨𝐬𝐮𝐬 (𝐒𝐋𝐄), a complex autoimmune disease. Recent research shows that the absence of NOX2 exacerbates SLE symptoms, shedding light on its multifaceted role in immune regulation. 🔍 𝐁𝐲 𝐮𝐭𝐢𝐥𝐢𝐳𝐢𝐧𝐠 𝐜𝐨𝐧𝐝𝐢𝐭𝐢𝐨𝐧𝐚𝐥 𝐤𝐧𝐨𝐜𝐤𝐨𝐮𝐭 𝐦𝐨𝐝𝐞𝐥𝐬 in MRL.Faslpr SLE-prone mice, researchers discovered that deleting NOX2 in macrophages worsens nephritis. Surprisingly, knocking out NOX2 in B cells resulted in severe glomerulonephritis and interstitial nephritis, comparable to the effects of global NOX2 deletion. 🌟 𝐓𝐡𝐞 𝐬𝐭𝐮𝐝𝐲 𝐡𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐓𝐋𝐑𝟕 𝐚𝐬 𝐚 𝐤𝐞𝐲 𝐝𝐫𝐢𝐯𝐞𝐫 𝐨𝐟 𝐒𝐋𝐄 𝐩𝐚𝐭𝐡𝐨𝐥𝐨𝐠𝐲, with NOX2 acting as a crucial regulator that suppresses TLR7-mediated NF-κB signalling in B cells. This dual role emphasizes the importance of NOX2 in both myeloid and B cell compartments in the context of SLE. 🤔 𝐇𝐨𝐰 𝐦𝐢𝐠𝐡𝐭 𝐭𝐡𝐞𝐬𝐞 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐢𝐧𝐭𝐨 𝐍𝐎𝐗𝟐 𝐚𝐧𝐝 𝐓𝐋𝐑𝟕 𝐬𝐢𝐠𝐧𝐚𝐥𝐢𝐧𝐠 𝐢𝐧𝐟𝐨𝐫𝐦 𝐧𝐞𝐰 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐟𝐨𝐫 𝐚𝐮𝐭𝐨𝐢𝐦𝐦𝐮𝐧𝐞 𝐝𝐢𝐬𝐞𝐚𝐬𝐞𝐬? 👣 Follow me for more great content on cutting-edge innovations! https://lnkd.in/dGihRk-q #Autoimmunity #Lupus #Immunology

🧠 𝐂𝐨𝐮𝐥𝐝 𝐄𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐞𝐝 𝐓 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐁𝐞 𝐭𝐡𝐞 𝐀𝐧𝐬𝐰𝐞𝐫 𝐭𝐨 𝐂𝐞𝐧𝐭𝐫𝐚𝐥 𝐍𝐞𝐫𝐯𝐨𝐮𝐬 𝐒𝐲𝐬𝐭𝐞𝐦 𝐈𝐧𝐣𝐮𝐫𝐲? 🧠 Uncover the potential of T cell therapy in revolutionizing treatment approaches for central nervous system injuries. 💥 𝐓𝐫𝐚𝐮𝐦𝐚𝐭𝐢𝐜 𝐢𝐧𝐣𝐮𝐫𝐢𝐞𝐬 𝐭𝐨 𝐭𝐡𝐞 𝐜𝐞𝐧𝐭𝐫𝐚𝐥 𝐧𝐞𝐫𝐯𝐨𝐮𝐬 𝐬𝐲𝐬𝐭𝐞𝐦 (𝐂𝐍𝐒) pose a significant challenge, affecting millions globally. Despite the presence of T cells at injury sites, our understanding of their roles and antigen specificity has been limited, hindering the advancement of immune-mediated therapies. 🧬 𝐀 𝐫𝐞𝐜𝐞𝐧𝐭 𝐬𝐭𝐮𝐝𝐲 𝐮𝐭𝐢𝐥𝐢𝐳𝐢𝐧𝐠 𝐬𝐢𝐧𝐠𝐥𝐞-𝐜𝐞𝐥𝐥 𝐑𝐍𝐀 𝐬𝐞𝐪𝐮𝐞𝐧𝐜𝐢𝐧𝐠 shed light on the clonal expansion of T cells in spinal cord injury models, revealing that CD4+ T cell clones show antigen specificity toward self-peptides from myelin and neuronal proteins. This insight is crucial as it informs the development of targeted therapies. 🔀 𝐁𝐲 𝐞𝐦𝐩𝐥𝐨𝐲𝐢𝐧𝐠 𝐦𝐑𝐍𝐀-𝐛𝐚𝐬𝐞𝐝 𝐓 𝐜𝐞𝐥𝐥 𝐫𝐞𝐜𝐞𝐩𝐭𝐨𝐫 (𝐓𝐂𝐑) 𝐫𝐞𝐜𝐨𝐧𝐬𝐭𝐢𝐭𝐮𝐭𝐢𝐨𝐧, researchers engineered transiently autoimmune T cells designed to minimize the risks associated with prolonged activation of self-reactive T cells. Remarkably, these engineered T cells demonstrated significant neuroprotective effects in CNS injury models, partly through the modulation of myeloid cells via IFNγ. 💡 𝐓𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐧𝐨𝐭 𝐨𝐧𝐥𝐲 𝐮𝐧𝐜𝐨𝐯𝐞𝐫𝐬 𝐭𝐡𝐞 𝐦𝐞𝐜𝐡𝐚𝐧𝐢𝐬𝐭𝐢𝐜 𝐛𝐚𝐬𝐢𝐬 for the neuroprotective function of injury-responsive T cells but also paves the way for future T cell therapies aimed at addressing CNS injuries effectively. 🤔 𝐇𝐨𝐰 𝐝𝐨 𝐲𝐨𝐮 𝐞𝐧𝐯𝐢𝐬𝐢𝐨𝐧 𝐭𝐡𝐞 𝐫𝐨𝐥𝐞 𝐨𝐟 𝐞𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐞𝐝 𝐓 𝐜𝐞𝐥𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐞𝐯𝐨𝐥𝐯𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐞 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐨𝐟 𝐜𝐞𝐧𝐭𝐫𝐚𝐥 𝐧𝐞𝐫𝐯𝐨𝐮𝐬 𝐬𝐲𝐬𝐭𝐞𝐦 𝐢𝐧𝐣𝐮𝐫𝐢𝐞𝐬? 👣 Follow me for more great content on cutting-edge innovations! https://lnkd.in/d9C6pMkK #CNSInjury #TCellTherapy #Neuroprotection

🌍 𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐢𝐧𝐠 Altius Bioventures'𝐬 𝐓𝐡𝐞 𝐂𝐆𝐓 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐀𝐭𝐥𝐚𝐬 🌍 Explore how this innovative tool can help reshape the strategies and success of CGT companies. 🌱 𝐓𝐡𝐞 𝐂𝐆𝐓 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐀𝐭𝐥𝐚𝐬 𝐢𝐬 𝐝𝐞𝐬𝐢𝐠𝐧𝐞𝐝 𝐭𝐨 𝐦𝐚𝐩 𝐨𝐮𝐭 𝐭𝐡𝐞 𝐞𝐧𝐭𝐢𝐫𝐞 𝐞𝐜𝐨𝐬𝐲𝐬𝐭𝐞𝐦—from collection to manufacturing and delivery—making it an invaluable tool for anyone involved in the CGT space. 📌 𝐈𝐧 𝐚 𝐫𝐚𝐩𝐢𝐝𝐥𝐲 𝐞𝐯𝐨𝐥𝐯𝐢𝐧𝐠 𝐬𝐞𝐜𝐭𝐨𝐫, 𝐤𝐞𝐞𝐩𝐢𝐧𝐠 𝐮𝐩 𝐰𝐢𝐭𝐡 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐞𝐬, 𝐩𝐫𝐨𝐜𝐞𝐬𝐬𝐞𝐬, 𝐚𝐧𝐝 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧𝐬 𝐢𝐬 𝐤𝐞𝐲. The CGT Industry Atlas breaks the complexity into seven core elements, offering a clear and structured understanding of the landscape. Whether you're an executive formulating strategy, an investor shaping a portfolio, or an innovator driving breakthroughs, this resource is a game changer. 💼 𝐅𝐨𝐫 𝐄𝐱𝐞𝐜𝐮𝐭𝐢𝐯𝐞𝐬 This Atlas serves as a strategic guide, helping industry leaders identify their niche, discover potential partnerships, and pinpoint opportunities for innovation and growth. 💰 𝐅𝐨𝐫 𝐈𝐧𝐯𝐞𝐬𝐭𝐨𝐫𝐬  The CGT Industry Atlas offers a forward-looking overview of the ecosystem, allowing investors to develop diversified strategies by recognizing the most promising tools, technologies, and services. 💡 𝐅𝐨𝐫 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐨𝐫𝐬 Visualize the key areas in CGT, from material sourcing to product administration, helping you stay at the forefront of this cutting-edge field. 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐭𝐡𝐞 𝐂𝐆𝐓 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐀𝐭𝐥𝐚𝐬 𝐚𝐧𝐝 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐡𝐨𝐰 𝐢𝐭 𝐜𝐚𝐧 𝐞𝐧𝐡𝐚𝐧𝐜𝐞 𝐲𝐨𝐮𝐫 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐲 𝐭𝐨𝐝𝐚𝐲: https://lnkd.in/dfyYCMbS 👣 Follow me for more great content! #CGT #CellTherapy #Innovation

🌍 REGiMMUNE Corporation and Kiji Therapeutics are merging to form REGiMMUNE/Kiji TX, a pioneering company set to become a 𝐠𝐥𝐨𝐛𝐚𝐥 𝐥𝐞𝐚𝐝𝐞𝐫 𝐢𝐧 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐓 𝐜𝐞𝐥𝐥 (𝐓𝐫𝐞𝐠) 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬! 🌍 🤝 𝐓𝐡𝐢𝐬 𝐦𝐞𝐫𝐠𝐞𝐫 𝐜𝐨𝐦𝐛𝐢𝐧𝐞𝐬 𝐭𝐰𝐨 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 with complementary expertise, focusing on the modulation of Treg functions to address unmet medical needs in immune-oncology and autoimmune diseases. 🧪 REGiMMUNE Corporation'𝐬 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐞 𝐞𝐧𝐡𝐚𝐧𝐜𝐞𝐫𝐬 𝐚𝐧𝐝 Kiji Therapeutics'𝐬 𝐜𝐮𝐭𝐭𝐢𝐧𝐠-𝐞𝐝𝐠𝐞 𝐦𝐮𝐥𝐭𝐢𝐠𝐞𝐧𝐞 𝐞𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐞𝐝 𝐬𝐭𝐞𝐦 𝐜𝐞𝐥𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 will provide a robust platform to tackle challenges like graft-versus-host disease (GvHD), inflammatory bowel disease (IBD), and psoriasis. 🎯 𝐖𝐢𝐭𝐡 𝐚 𝐩𝐫𝐨𝐦𝐢𝐬𝐢𝐧𝐠 𝐩𝐢𝐩𝐞𝐥𝐢𝐧𝐞 𝐭𝐚𝐫𝐠𝐞𝐭𝐢𝐧𝐠 𝐟𝐨𝐮𝐫 𝐤𝐞𝐲 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬, REGiMMUNE/Kiji TX is gearing up for a planned IPO in mid-2025 on Taiwan’s Emerging Stock Market. This strategic move not only strengthens their market position but also sets the stage for ground-breaking advancements in the field. 💡 "𝐓𝐫𝐞𝐠𝐬 𝐡𝐚𝐯𝐞 𝐩𝐫𝐨𝐯𝐞𝐧 𝐭𝐨 𝐛𝐞 𝐚 𝐥𝐞𝐚𝐝𝐢𝐧𝐠 𝐩𝐫𝐨𝐦𝐢𝐬𝐢𝐧𝐠 𝐦𝐨𝐝𝐚𝐥𝐢𝐭𝐲 in cell and gene therapy," said Miguel Forte, CEO of Kiji Therapeutics. This merger will leverage small molecules, monoclonal antibodies, and cell therapies, positioning the new entity as a versatile powerhouse in Treg modulation. 👥 𝐀𝐬 𝐭𝐡𝐞 𝐭𝐞𝐚𝐦, 𝐥𝐞𝐝 𝐛𝐲 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞𝐝 𝐥𝐞𝐚𝐝𝐞𝐫𝐬 𝐟𝐫𝐨𝐦 𝐛𝐨𝐭𝐡 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬, 𝐛𝐞𝐠𝐢𝐧𝐬 𝐭𝐡𝐢𝐬 𝐣𝐨𝐮𝐫𝐧𝐞𝐲, their goal is clear: to unlock the full potential of Tregs for the benefit of patients worldwide. 💊 𝐈𝐭’𝐬 𝐚𝐥𝐬𝐨 𝐰𝐨𝐫𝐭𝐡 𝐧𝐨𝐭𝐢𝐧𝐠 𝐭𝐡𝐚𝐭 𝐛𝐢𝐠 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐡𝐚𝐯𝐞 𝐛𝐞𝐞𝐧 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐢𝐧𝐠𝐥𝐲 𝐢𝐧𝐭𝐞𝐫𝐞𝐬𝐭𝐞𝐝 𝐢𝐧 𝐓𝐫𝐞𝐠𝐬. Notable collaborations include Eli Lilly and Company’s licensing deal with TRexBio, Bristol Myers Squibb’s partnership with GentiBio, AstraZeneca’s work with Quell Therapeutics, Regeneron's deal with Sonoma Biotherapeutics, and Dr. Reddy's Laboratories collaboration with Coya Therapeutics, Inc. Follow me for more biotech and science news! 👣 #Treg #CellTherapy #Innovation

🏃 𝐂𝐨𝐮𝐥𝐝 𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐯𝐞 𝐒𝐢𝐧𝐠𝐥𝐞-𝐂𝐞𝐥𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐑𝐞𝐯𝐞𝐚𝐥 𝐈𝐦𝐦𝐮𝐧𝐞 𝐄𝐯𝐚𝐬𝐢𝐨𝐧 𝐌𝐞𝐜𝐡𝐚𝐧𝐢𝐬𝐦𝐬 𝐢𝐧 𝐂𝐨𝐥𝐨𝐫𝐞𝐭𝐚𝐥 𝐂𝐚𝐧𝐜𝐞𝐫? 🏃 Explore how this cutting-edge analysis method can provide new insights into cancer immunology. 🧬 𝐔𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠 𝐭𝐡𝐞 𝐭𝐮𝐦𝐨𝐮𝐫 𝐦𝐢𝐜𝐫𝐨𝐞𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭 (𝐓𝐌𝐄) 𝐢𝐬 𝐜𝐫𝐮𝐜𝐢𝐚𝐥 for addressing colorectal cancer (CRC) progression and treatment response. A recent study leveraged single-cell transcriptomic data from around 200 donors to explore the complexities of the TME, uncovering significant interindividual heterogeneities that have been overlooked in CRC research. 🧪 𝐓𝐡𝐢𝐬 𝐜𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐫𝐞𝐯𝐞𝐚𝐥𝐞𝐝 𝐚 𝐮𝐧𝐢𝐪𝐮𝐞 𝐬𝐮𝐛𝐬𝐞𝐭 of tumour-specific endothelial cells with the potential to recruit T cells, highlighting new avenues for enhancing immune response within the TME. By stratifying patients based on TME heterogeneity, the researchers identified divergent TME subtypes where cancer cells deploy different immune evasion strategies. 📊 𝐈𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭𝐥𝐲, 𝐭𝐡𝐞 𝐢𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐬𝐢𝐧𝐠𝐥𝐞-𝐜𝐞𝐥𝐥 𝐩𝐫𝐨𝐟𝐢𝐥𝐢𝐧𝐠 with risk genes from genome-wide association studies emphasized the pivotal role of stromal cells in CRC genetic susceptibility. These findings could pave the way for developing personalized immune therapies that target specific mechanisms of immune evasion. 🤔 𝐇𝐨𝐰 𝐜𝐨𝐮𝐥𝐝 𝐭𝐡𝐞𝐬𝐞 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐢𝐧𝐭𝐨 𝐭𝐡𝐞 𝐓𝐌𝐄 𝐚𝐧𝐝 𝐢𝐦𝐦𝐮𝐧𝐞 𝐞𝐯𝐚𝐬𝐢𝐨𝐧 𝐫𝐞𝐬𝐡𝐚𝐩𝐞 𝐨𝐮𝐫 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡 𝐭𝐨 𝐭𝐫𝐞𝐚𝐭𝐢𝐧𝐠 𝐜𝐨𝐥𝐨𝐫𝐞𝐜𝐭𝐚𝐥 𝐜𝐚𝐧𝐜𝐞𝐫? 👣 Follow me for more great content on cutting-edge innovations! #ColorectalCancer #TumorMicroenvironment #PersonalizedMedicine

🐾 𝐓𝐨𝐠𝐞𝐭𝐡𝐞𝐫, 𝐎𝐭𝐢𝐬 𝐚𝐧𝐝 𝐈 𝐖𝐚𝐥𝐤𝐞𝐝 𝟏𝟓𝟎𝐤𝐦 𝐟𝐨𝐫 𝐌𝐒 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 🐾 🚶♂️🐕 𝐌𝐞 𝐚𝐧𝐝 𝐦𝐲 𝐛𝐚𝐛𝐲 𝐛𝐨𝐲 𝐎𝐭𝐢𝐬 (𝐦𝐲 𝟑-𝐲𝐞𝐚𝐫-𝐨𝐥𝐝 𝐁𝐨𝐬𝐭𝐨𝐧 𝐓𝐞𝐫𝐫𝐢𝐞𝐫) have officially completed the 𝐌𝐲 𝐌𝐒 𝐖𝐨𝐨𝐟 𝟏𝟓𝟎𝐤𝐦 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞 to raise funds for the MS Society, and I couldn’t be prouder of my little walking buddy. ❤️ 𝐓𝐡𝐢𝐬 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞 𝐢𝐬 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥 𝐭𝐨 𝐦𝐞 – none of us knows when a devastating illness like MS might affect the people we care about. 🌻 𝐒𝐨𝐦𝐞 𝐝𝐚𝐲𝐬, 𝐢𝐭’𝐬 𝐛𝐞𝐞𝐧 𝐞𝐚𝐬𝐢𝐞𝐫 𝐭𝐡𝐚𝐧 𝐨𝐭𝐡𝐞𝐫𝐬 𝐭𝐨 𝐥𝐚𝐜𝐞 𝐮𝐩 𝐚𝐧𝐝 𝐡𝐢𝐭 𝐭𝐡𝐞 𝐭𝐫𝐚𝐢𝐥, and this journey has made me more conscious of how much our mental health impacts everything we do – even simple walks. 💪 𝐅𝐨𝐫 𝐭𝐡𝐨𝐬𝐞 𝐨𝐟 𝐮𝐬 𝐥𝐮𝐜𝐤𝐲 𝐞𝐧𝐨𝐮𝐠𝐡 𝐭𝐨 𝐡𝐚𝐯𝐞 𝐨𝐮𝐫 𝐡𝐞𝐚𝐥𝐭𝐡, it’s easy to take mobility and motivation for granted. This experience reminded me of the incredible resilience of those living with MS and the everyday battles they face. 🧠 𝐌𝐒 𝐚𝐟𝐟𝐞𝐜𝐭𝐬 𝐨𝐯𝐞𝐫 𝟏𝟓𝟎,𝟎𝟎𝟎 𝐩𝐞𝐨𝐩𝐥𝐞 𝐢𝐧 𝐭𝐡𝐞 𝐔𝐊, and the funds raised are critical in helping researchers find a cure. Just £50 can fund an hour of microscope time for vital research, while £100 helps analyse blood samples that could unlock new treatments. Every single step we’ve taken brings us closer to a future free from MS. 💖 𝐓𝐨 𝐞𝐯𝐞𝐫𝐲𝐨𝐧𝐞 𝐰𝐡𝐨 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐞𝐝 𝐮𝐬, whether through donations, words of encouragement, or cheering us on from afar – thank you. Your generosity is making a real impact, one step at a time. 🙏 𝐇𝐞𝐫𝐞’𝐬 𝐭𝐨 𝐚 𝐟𝐮𝐭𝐮𝐫𝐞 𝐰𝐡𝐞𝐫𝐞 𝐰𝐞 𝐜𝐚𝐧 𝐬𝐭𝐨𝐩 𝐌𝐒 𝐟𝐨𝐫 𝐠𝐨𝐨𝐝. 𝐎𝐭𝐢𝐬 𝐚𝐧𝐝 𝐈 𝐜𝐨𝐮𝐥𝐝𝐧’𝐭 𝐡𝐚𝐯𝐞 𝐝𝐨𝐧𝐞 𝐢𝐭 𝐰𝐢𝐭𝐡𝐨𝐮𝐭 𝐲𝐨𝐮. #MS #MyMSWoof #EndMS

🔬 𝐖𝐢𝐥𝐥 𝐓𝐂𝐑/𝐂𝐃𝟑-𝐛𝐚𝐬𝐞𝐝 𝐬𝐲𝐧𝐭𝐡𝐞𝐭𝐢𝐜 𝐜𝐨𝐧𝐬𝐭𝐫𝐮𝐜𝐭𝐬 𝐁𝐞 𝐓𝐡𝐞 𝐍𝐞𝐱𝐭 𝐁𝐢𝐠 𝐋𝐞𝐚𝐩 𝐢𝐧 𝐂𝐚𝐧𝐜𝐞𝐫 𝐈𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲? 🔬 Discover the promise of TCR/CD3-based synthetic constructs (TCC) in advancing cancer treatment and patient outcomes. 🧪 𝐓𝐫𝐚𝐝𝐢𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐀𝐑 𝐓 𝐜𝐞𝐥𝐥𝐬, 𝐰𝐡𝐢𝐥𝐞 𝐩𝐫𝐨𝐦𝐢𝐬𝐢𝐧𝐠, 𝐡𝐚𝐯𝐞 𝐥𝐢𝐦𝐢𝐭𝐚𝐭𝐢𝐨𝐧𝐬 due to low antigen sensitivity and a loss of effector functions over time. But researchers have found a new approach with TCR/CD3-based synthetic antigen receptors (TCC), which could significantly enhance the effectiveness of T cell-based cancer therapies. 💥 𝐓𝐂𝐂 𝐜𝐨𝐧𝐬𝐭𝐫𝐮𝐜𝐭𝐬 𝐬𝐡𝐨𝐰 𝐚 𝐫𝐞𝐦𝐚𝐫𝐤𝐚𝐛𝐥𝐞 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐞 𝐢𝐧 𝐚𝐧𝐭𝐢𝐠𝐞𝐧 𝐬𝐞𝐧𝐬𝐢𝐭𝐢𝐯𝐢𝐭𝐲—up to a thousandfold—compared to second-generation CAR T cells. Even better, they deliver this enhanced sensitivity without triggering harmful nonspecific signalling, a common issue in CAR–T therapies. 🎯 𝐔𝐧𝐥𝐢𝐤𝐞 𝐜𝐨𝐧𝐯𝐞𝐧𝐭𝐢𝐨𝐧𝐚𝐥 𝐓 𝐜𝐞𝐥𝐥𝐬, which rely on CD4 or CD8 coreceptors for activation, TCC-modified T cells don't need these engagements, making them highly effective at targeting antigens even when they're in low abundance. This opens up exciting possibilities for achieving a more durable and precise anticancer response. ❓𝐂𝐨𝐮𝐥𝐝 𝐓𝐂𝐂 𝐜𝐨𝐧𝐬𝐭𝐫𝐮𝐜𝐭𝐬 𝐛𝐞 𝐭𝐡𝐞 𝐤𝐞𝐲 𝐭𝐨 𝐨𝐯𝐞𝐫𝐜𝐨𝐦𝐢𝐧𝐠 𝐭𝐡𝐞 𝐜𝐮𝐫𝐫𝐞𝐧𝐭 𝐥𝐢𝐦𝐢𝐭𝐚𝐭𝐢𝐨𝐧𝐬 𝐨𝐟 𝐂𝐀𝐑 𝐓 𝐜𝐞𝐥𝐥𝐬? 👣 Follow me for more great content on cutting-edge innovations! #Immunotherapy #CancerResearch #TCellTherapy

💵 𝐌𝐚𝐬𝐭𝐞𝐫𝐢𝐧𝐠 𝐒𝐭𝐚𝐫𝐭-𝐮𝐩 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 𝐒𝐭𝐚𝐠𝐞𝐬 💵 Discover the strategies for navigating each funding stage and propelling your start-up forward. 🌟 𝐓𝐮𝐫𝐧𝐢𝐧𝐠 𝐚 𝐛𝐫𝐢𝐥𝐥𝐢𝐚𝐧𝐭 𝐢𝐝𝐞𝐚 𝐢𝐧𝐭𝐨 𝐚 𝐭𝐡𝐫𝐢𝐯𝐢𝐧𝐠 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 involves understanding various funding stages. Each stage plays a crucial role in the start-up journey, from initial concept to potential public offering. 🔍 𝐏𝐫𝐞-𝐒𝐞𝐞𝐝 𝐒𝐭𝐚𝐠𝐞: This is the foundational phase where start-ups validate their idea and begin gathering initial support. Funding at this stage, typically between $100k and $1M, often comes from family, friends, and early investors. It's all about laying the groundwork and setting up the business structure. 💡 𝐒𝐞𝐞𝐝 𝐅𝐮𝐧𝐝𝐢𝐧𝐠: In this stage, startups focus on proving their business model and attracting investors. Seed funding, generally ranging from $1M to $4M, helps build and refine the product or service while establishing a customer base. It's a time for demonstrating traction and preparing for larger-scale growth. 🚀 𝐒𝐞𝐫𝐢𝐞𝐬 𝐀: By Series A, start-ups should have a proven track record and a clear growth strategy. This stage involves selling preferred stock to investors, focusing on scaling operations and solidifying market presence. Series A funding is crucial for expanding the business and reaching new milestones. 📈 𝐒𝐞𝐫𝐢𝐞𝐬 𝐁: Series B funding supports further expansion and development. With a solid business foundation, this round is used to enhance operations, invest in new technologies, and increase market share. The funding helps scale the business and prepare for more significant growth. 🌍 𝐒𝐞𝐫𝐢𝐞𝐬 𝐂: At this stage, companies aim for major expansion, such as entering new markets or acquiring other businesses. Series C funding, which can range from $30M to $100M, supports these large-scale initiatives and drives significant growth. It's about leveraging past success to achieve broader objectives. 💰 𝐒𝐞𝐫𝐢𝐞𝐬 𝐃 & 𝐈𝐏𝐎: Series D funding addresses any remaining challenges and prepares the company for an Initial Public Offering (IPO). An IPO involves offering shares to the public, providing substantial capital and increasing market visibility. This stage signifies a major transition to becoming a publicly traded company. 🔑 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 𝐒𝐨𝐮𝐫𝐜𝐞𝐬: Start-ups explore various funding sources throughout these stages, including angel investors, venture capitalists, and government grants. Each source offers different benefits and caters to specific stages of the business's growth. #StartupFunding #Entrepreneurship #FundingStages

🧂 𝐂𝐨𝐮𝐥𝐝 𝐬𝐚𝐥𝐭 𝐛𝐞 𝐚 𝐬𝐞𝐜𝐫𝐞𝐭 𝐰𝐞𝐚𝐩𝐨𝐧 𝐢𝐧 𝐟𝐢𝐠𝐡𝐭𝐢𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫? 🧂 Explore the surprising potential of salt in enhancing the effectiveness of cancer therapies. 🧬 𝐈𝐭 𝐭𝐮𝐫𝐧𝐬 𝐨𝐮𝐭 𝐭𝐡𝐚𝐭 𝐬𝐨𝐝𝐢𝐮𝐦 𝐜𝐡𝐥𝐨𝐫𝐢𝐝𝐞 (𝐍𝐚𝐂𝐥) 𝐦𝐚𝐲 𝐩𝐥𝐚𝐲 𝐚 𝐜𝐫𝐮𝐜𝐢𝐚𝐥 𝐫𝐨𝐥𝐞 in enhancing the effectiveness of T cells, which are responsible for killing cancer cells. In patients with breast cancer, an enrichment of sodium was found in solid tumours. 🔋 𝐓𝐡𝐞 𝐩𝐫𝐞𝐬𝐞𝐧𝐜𝐞 𝐨𝐟 𝐍𝐚𝐂𝐥 𝐛𝐨𝐨𝐬𝐭𝐬 𝐭𝐡𝐞 𝐦𝐞𝐭𝐚𝐛𝐨𝐥𝐢𝐜 𝐟𝐢𝐭𝐧𝐞𝐬𝐬 of human CD8+ T cells, making them more efficient in their activation and ability to target cancer cells. This effect translates into improved tumour cell killing, both in the lab and in living organisms. ⚡ 𝐇𝐨𝐰 𝐝𝐨𝐞𝐬 𝐭𝐡𝐢𝐬 𝐰𝐨𝐫𝐤? NaCl increases the activity of Na+/K+-ATPase, leading to membrane hyperpolarization. This change enhances the calcium influx triggered by T cell receptors, amplifying the antitumor response. 🏥 𝐓𝐡𝐞𝐬𝐞 𝐟𝐢𝐧𝐝𝐢𝐧𝐠𝐬 𝐬𝐮𝐠𝐠𝐞𝐬𝐭 𝐭𝐡𝐚𝐭 𝐬𝐨𝐝𝐢𝐮𝐦 𝐜𝐡𝐥𝐨𝐫𝐢𝐝𝐞 could be a positive regulator of acute antitumor immunity, potentially used to improve therapies like CAR T cells. 💡 𝐖𝐡𝐚𝐭 𝐚𝐫𝐞 𝐲𝐨𝐮𝐫 𝐭𝐡𝐨𝐮𝐠𝐡𝐭𝐬 𝐨𝐧 𝐬𝐨𝐝𝐢𝐮𝐦 𝐚𝐬 𝐚 𝐩𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐚𝐥𝐥𝐲 𝐢𝐧 𝐜𝐚𝐧𝐜𝐞𝐫 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭? 𝐂𝐨𝐮𝐥𝐝 𝐭𝐡𝐢𝐬 𝐥𝐞𝐚𝐝 𝐭𝐨 𝐧𝐞𝐰 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡𝐞𝐬 𝐢𝐧 𝐢𝐦𝐦𝐮𝐧𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐲? 👣 Follow me for more great content on cutting-edge research and breakthroughs! #CancerResearch #TCellTherapy #Immunotherapy

💡𝐂𝐨𝐮𝐥𝐝 𝐂𝐗𝐂𝐑𝟒-𝐞𝐧𝐫𝐢𝐜𝐡𝐞𝐝 𝐓𝐫𝐞𝐠𝐬 𝐁𝐞 𝐓𝐡𝐞 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐭𝐨 𝐂𝐨𝐧𝐭𝐫𝐨𝐥𝐥𝐢𝐧𝐠 𝐈𝐧𝐟𝐥𝐚𝐦𝐦𝐚𝐭𝐢𝐨𝐧? 💡 Discover the potential of CXCR4-enriched Tregs in shaping the future of inflammation treatment. 🧬 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐯𝐞𝐚𝐥𝐬 𝐭𝐡𝐚𝐭 CXCR4-enriched T regulatory cells (TregCXCR4) could be game-changers in resolving inflammation. These cells show an upregulation of important markers like FoxP3, Helios, and IL-10, which play a role in immune regulation. 🔥 𝐁𝐮𝐭 𝐡𝐞𝐫𝐞’𝐬 𝐭𝐡𝐞 𝐫𝐞𝐚𝐥𝐥𝐲 𝐜𝐨𝐨𝐥 𝐩𝐚𝐫𝐭: TregCXCR4 cells move faster towards the CXCL12/SDF-1α ligand than standard Tregs. This faster migration gives them an edge in reducing inflammation where it matters most—like in the bone marrow. 🦴 𝐎𝐧𝐜𝐞 𝐭𝐡𝐞𝐬𝐞 𝐜𝐞𝐥𝐥𝐬 𝐡𝐨𝐦𝐞 𝐭𝐨 𝐭𝐡𝐞 𝐛𝐨𝐧𝐞 𝐦𝐚𝐫𝐫𝐨𝐰, they help reduce harmful inflammatory markers such as CD8, IFN-γ, and TNF-α. By doing so, they help to create a more balanced immune response and decrease overall inflammation. 💉 𝐓𝐡𝐞 𝐬𝐭𝐮𝐝𝐲 𝐚𝐥𝐬𝐨 𝐬𝐡𝐨𝐰𝐞𝐝 𝐭𝐡𝐚𝐭 TregCXCR4 cells significantly lower levels of TGF-β1/β2 and IFN-γ in plasma, further demonstrating their potential to combat inflammation. With faster migration and stronger homing capabilities, these cells could be key players in the fight against immune-related diseases. ❓ 𝐖𝐡𝐚𝐭 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐨𝐫 𝐨𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐝𝐨 𝐲𝐨𝐮 𝐭𝐡𝐢𝐧𝐤 𝐥𝐢𝐞 𝐚𝐡𝐞𝐚𝐝 𝐢𝐧 𝐭𝐫𝐚𝐧𝐬𝐥𝐚𝐭𝐢𝐧𝐠 𝐭𝐡𝐞𝐬𝐞 𝐟𝐢𝐧𝐝𝐢𝐧𝐠𝐬 𝐭𝐨 𝐭𝐡𝐞 𝐜𝐥𝐢𝐧𝐢𝐜? 👣 Follow me for more great content on cutting-edge research and innovations in science! #Immunology #Tregs #Inflammation